Find Clinical Trials
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.
Servier Protocol Code:
CL3-20098-062
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S)
EudraCT Number:
2008-004642-92
Find a recruiting site
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
Results
English (USA)Interventions / Treatments
The treatment(s) given to the participants in the study.
- Major Depressive Disorder
- AGOMELATINE
- S020098
Other study id numbers
Other identification numbers the study may be known by.
- CL3-20098-062